Raymond Woo Sells 705 Shares of CeriBell (NASDAQ:CBLL) Stock

CeriBell, Inc. (NASDAQ:CBLL) CTO Raymond Woo sold 705 shares of the firm’s stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $19.79, for a total transaction of $13,951.95. Following the sale, the chief technology officer owned 166,912 shares of the company’s stock, valued at $3,303,188.48. This trade represents a 0.42% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Raymond Woo also recently made the following trade(s):

• On Friday, January 2nd, Raymond Woo sold 11,112 shares of CeriBell stock. The stock was sold at an average price of $21.18, for a total transaction of $235,352.16.
• On Monday, December 1st, Raymond Woo sold 11,112 shares of CeriBell stock. The shares were sold at an average price of $12.28, for a total value of $136,455.36.

CeriBell Stock Performance

NASDAQ:CBLL opened at $19.39 on Friday. The company has a market capitalization of $719.29 million, a P/E ratio of -13.19 and a beta of 1.03. The business has a fifty day simple moving average of $21.17 and a two-hundred day simple moving average of $16.21. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.73 and a quick ratio of 12.25. CeriBell, Inc. has a 1 year low of $10.01 and a 1 year high of $25.37.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings results on Tuesday, February 24th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.07. CeriBell had a negative return on equity of 31.77% and a negative net margin of 59.97%.The company had revenue of $24.78 million during the quarter, compared to the consensus estimate of $23.95 million. On average, analysts expect that CeriBell, Inc. will post -2.46 earnings per share for the current year.

Institutional Trading of CeriBell

A number of large investors have recently modified their holdings of the business. Peregrine Capital Management LLC purchased a new stake in CeriBell in the second quarter valued at approximately $6,399,000. Emerald Advisers LLC lifted its holdings in shares of CeriBell by 3.9% during the 2nd quarter. Emerald Advisers LLC now owns 125,869 shares of the company’s stock worth $2,358,000 after acquiring an additional 4,727 shares during the last quarter. Emerald Mutual Fund Advisers Trust grew its position in CeriBell by 26.1% in the second quarter. Emerald Mutual Fund Advisers Trust now owns 98,185 shares of the company’s stock worth $1,839,000 after acquiring an additional 20,350 shares in the last quarter. TimesSquare Capital Management LLC increased its stake in CeriBell by 48.5% in the second quarter. TimesSquare Capital Management LLC now owns 796,945 shares of the company’s stock valued at $14,927,000 after acquiring an additional 260,116 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in CeriBell by 55.4% during the second quarter. Geode Capital Management LLC now owns 447,936 shares of the company’s stock valued at $8,391,000 after purchasing an additional 159,698 shares in the last quarter.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on CBLL. TD Cowen reissued a “buy” rating on shares of CeriBell in a report on Tuesday, December 9th. BTIG Research reissued a “buy” rating and set a $30.00 price objective on shares of CeriBell in a report on Wednesday, January 28th. Canaccord Genuity Group upped their price target on CeriBell from $29.00 to $30.00 and gave the company a “buy” rating in a research report on Wednesday, December 17th. Finally, JPMorgan Chase & Co. cut their price objective on shares of CeriBell from $21.00 to $17.00 and set an “overweight” rating for the company in a research report on Wednesday, November 5th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $24.67.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.